Neoantigens represent promising targets for personalized cancer vaccine strategies.
However, the feasibility of this approach in lower mutational burden tumors like glioblastoma …

Malignant gliomas are the most common primary brain cancer diagnosed and still carry a
poor prognosis despite aggressive multimodal management. Despite the continued …

The “cancer immunogenomics” paradigm has facilitated the search for tumor-specific
antigens over the last 4 years by applying comprehensive cancer genomics to tumor antigen …

Glioblastoma (GBM) is resistant to multimodality therapeutic approaches. A high burden of
tumor-specific mutant peptides (neoantigens) correlates with better survival and response to …

Cancer vaccines can generate and amplify tumor-specific T cell responses with the promise
to provide long-term control of cancer. All cancer cells harbor genetic alterations encoding …

Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses, and can function as bona …

Immunotherapy applications to glioblastoma represent a new treatment frontier. Antigen-
targeted immunotherapy approaches hold enormous potential to elicit antigen-specific anti …

Purpose: The low mutational load of some cancers is considered one reason for the difficulty
to develop effective tumor vaccines. To overcome this problem, we developed a strategy to …

Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

The adoptive transfer of naturally occurring T cells that recognize cancer neoantigens has
led to durable tumor regressions in select patients with cancer. However, it remains …